Status:
COMPLETED
S0000B: Vitamin E and/or Selenium in Preventing Cataract and Age-Related Macular Degeneration in Men on SELECT SWOG-S0000
Lead Sponsor:
SWOG Cancer Research Network
Collaborating Sponsors:
National Cancer Institute (NCI)
National Eye Institute (NEI)
Conditions:
Cataract
Macular Degeneration
Eligibility:
MALE
50-120 years
Phase:
PHASE3
Brief Summary
RATIONALE: Aging may affect a person's vision. Vitamin E and/or selenium may help prevent cataracts or age-related macular degeneration in men receiving these drugs as part of a clinical trial for the...
Detailed Description
OBJECTIVES: Primary * To test whether vitamin E and/or selenium reduces the risk of visually significant age-related macular degeneration (AMD) in men enrolled on SELECT (SWOG-S0000). * To test whet...
Eligibility Criteria
Inclusion
- DISEASE CHARACTERISTICS:
- Enrolled on the Selenium and Vitamin E Prostate Cancer Prevention Trial (SELECT) SWOG-S0000
- Diagnosis of 1 of the following:
- Age-related macular degeneration (AMD) at baseline or at follow-up
- Cataract or a cataract extraction at follow-up (Closed for accrual as of 10/01/29)
- Participants with a prior diagnosis of cataract at baseline followed by another cataract event (cataract diagnosis or a cataract extraction) at follow-up are not eligible
- Participants with a prior diagnosis of cataract at baseline followed by a diagnosis of AMD at follow-up are eligible
- PATIENT CHARACTERISTICS:
- See Disease Characteristics
- PRIOR CONCURRENT THERAPY:
- Not applicable
Exclusion
Key Trial Info
Start Date :
July 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2018
Estimated Enrollment :
13475 Patients enrolled
Trial Details
Trial ID
NCT00784225
Start Date
July 1 2004
End Date
May 1 2018
Last Update
August 14 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Harvard Medical School
Boston, Massachusetts, United States, 02215